

Ms. Kimberly Nearing, Head of Life Sciences at Cedrus Investments invited to participate in a Panel Discussion at the BIO CEO & investor conference in New York



PR NEWSWIRE ASIA (/SOURCE/PR-NEWSWIRE-ASIA) Mar 08, 2018

CEDRUS INVESTMENTS 素 微 思 投 資

HONG KONG, March 8, 2018 /PRNewswire/ -- The Managing Director, Head of Life Sciences at Cedrus

Investments ("Cedrus") (http://cedrusinvestments.com/), Ms. Kimberly Nearing, was invited to participate in a panel discussion at the 21<sup>st</sup> annual BIO CEO & Investor conference, which was held on February 12<sup>th</sup> and 13<sup>th</sup> in New York

City. It is one of the largest investor Conferences focusing both on established and emerging publicly-traded as well as select private biotechnology companies. By providing a neutral forum, the BIO CEO & Investor Conference offers institutional investors, industry analysts, and senior biotechnology executives the opportunity to shape the future investment landscape of the biotechnology industry.

The lively panel discussion Ms. Nearing took part in with industry leaders at the opening day of the conference was entitled "Updating Your China Growth Strategy: Opportunities in Investor and Regulatory Dynamism." The moderator of the panel was Mr. Joseph Damond, Executive Vice President, International Affairs, Biotechnology Innovation Organization (BIO). Panelists included:

Dr. Michael Keyoung, Managing Director and Head of North America, C-Bridge Capital;

Ms. Yuwen Liu, Founding Partner, BOHE Angel Fund; former Chairwoman & CEO, Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY);

Mr. Hummer Mars, Executive Director, China Group, Global Investment Banking Division, New York International Capital (N'IC);

 Dr. Dan Zhang, MD, Chairman, Fountain Medical Development Ltd., and

Ms. Kimberly Nearing, Managing Director, Head of Life Sciences, Cedrus Investments.

BIO's Mr. Damond said, "We were delighted to have Ms. Nearing's presence on the panel, we found her comments insightful, and her remarks together with observations about what has happened and is going to unfold in China's pharmaceutical market might be the impetus for executives of western companies in attendance to start including China in their market access plans if they do not have one in place yet. We hear from a lot of clients, and rightly so, that the value of their assets to potential partners in China has just increased because of the reduction in development time."

About Cedrus Investments

Cedrus Investments (http://www.cedrusinvestments.com/index.html) is a global boutique investment firm that offers expertise in private wealth management

(http://www.cedrusinvestments.com/our\_business/private\_wealth\_management.html), asset management (http://www.cedrusinvestments.com/our\_business/asset\_management.html) and financial advisory services (http://www.cedrusinvestments.com/our\_business/financial\_advisory\_services.html) to a clientele of leading institutional investors, corporations, family offices and high net worth individuals around the world.

For further information about Cedrus Investments, please visit www.cedrusinvestments.com (http://www.cedrusinvestments.com/).

Media Enquiry:

Cedrus Investments Ltd.

Amy Sin

+852-3519-2828

information@cedrusinvestments.com (mailto:information@cedrusinvestments.com)

Logo - http://photos.prnasia.com/prnh/20150930/8521506461L0G0 (http://photos.prnasia.com/prnh/20150930/8521506461L0G0)

PR Newswire

(http://en.prnasia.com/news-releases/)

news as

Purchase this article for (http://newslink.asiaone.com/ips/NewsPostEnquiryRequest.action) republication.

## MORE FROM ASIAONE



Be a man, apologise to Robert Kuok: MCA Youth chief to…



Malaysian celebrity Neelofa's company sorry for launching...



Singapore mumpreneurs: She holds a PhD in  $\cdots$